Linking immunity, epigenetics, and cancer in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 9, 2014, Pages 1638-1654

  Däbritz, Jan ^a,b,c   Menheniott, Trevelyan R ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adaptive immunity; Animal models; Colitis associated cancer; Crohn's disease; Cytokines; DNA methylation; Gene environment interactions; Histone modification; Host defense; Innate immunity; Micro RNAs; Microbiota; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; CANCER SUSCEPTIBILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLITIS; COMORBIDITY; DISEASE ASSOCIATION; DISEASE MODEL; DNA METHYLATION; DNA METHYLATION ASSAY; DNA MODIFICATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC REGULATION; GENOTYPE ENVIRONMENT INTERACTION; HISTONE MODIFICATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DYSREGULATION; IMMUNITY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE BIOPSY; INTESTINE FLORA; INTESTINE MUCOSA; NUCLEOSOME; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; ANIMAL; COMPLICATION; GENETICS; IMMUNOLOGY; NEOPLASMS;

ANIMALS; EPIGENOMICS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; NEOPLASMS;

EID: 84925878557     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000063     Document Type: Review

References (227)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
3. Di Sabatino A, Biancheri P, Rovedatti L, et al. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:368-371.
4. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057-1068.
5. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science. 2010;330:612-616.
6. Petronis A, Petroniene R. Epigenetics of inflammatory bowel disease. Gut. 2000;47:302-306.
7. Scarpa M, Stylianou E. Epigenetics: concepts and relevance to IBD pathogenesis. Inflamm Bowel Dis. 2012;18:1982-1996.
8. Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology. 2013;145:293-308.
9. Jenke AC, Zilbauer M. Epigenetics in inflammatory bowel disease. Curr Opin Gastroenterol. 2012;28:577-584.
10. Stylianou E. Epigenetics: the fine-tuner in inflammatory bowel disease? Curr Opin Gastroenterol. 2013;29:370-377.
11. Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases. Can J Gastroenterol. 2012;26:909-915.
12. Low D, Mizoguchi A, Mizoguchi E. DNA methylation in inflammatory bowel disease and beyond. World J Gastroenterol. 2013;19:5238-5249.
13. Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:187-193.
14. Iborra M, Bernuzzi F, Invernizzi P, et al. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev. 2012;11:305-314.
15. Waddington CH. An introduction to modern genetics. New York: Macmillan; 1939.
16. Waddington CH. The epigenotype. 1942. Int J Epidemiol. 2012;41:10-13.
17. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7: 299-313.
18. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res. 2007; 61:24R-29R.
19. Eccleston A, Cesari F, Skipper M. Transcription and epigenetics. Nature. 2013;502:461.
20. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature. 2000;405:482-485.
21. Tuorto F, Liebers R, Musch T, et al. RNA cytosine methylation by Dnmt2 and NSun2 promotes tRNA stability and protein synthesis. Nat Struct Mol Biol. 2012;19:900-905.
22. Greally JM. Short interspersed transposable elements (SINEs) are excluded from imprinted regions in the human genome. Proc Natl Acad Sci U S A. 2002;99:327-332.
23. Bourc'his D, Bestor TH. Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L. Nature. 2004;431:96-99.
24. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102: 10604-10609.
25. Javierre BM, Fernandez AF, Richter J, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010;20:170-179.
26. Kaminsky ZA, Tang T, Wang SC, et al. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet. 2009;41:240-245.
27. Renz H, von Mutius E, Brandtzaeg P, et al. Gene-environment interactions in chronic inflammatory disease. Nat Immunol. 2011;12:273-277.
28. Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet. 2011;13:97-109.
29. Painter RC, Osmond C, Gluckman P, et al. Transgenerational effects of prenatal exposure to the Dutch famine on neonatal adiposity and health in later life. BJOG. 2008;115:1243-1249.
30. Pembrey ME, Bygren LO, Kaati G, et al. Sex-specific, male-line transgenerational responses in humans. Eur J Hum Genet. 2006;14:159-166.
31. Tobi EW, Lumey LH, Talens RP, et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sexspecific. Hum Mol Genet. 2009;18:4046-4053.
32. Morgan HD, Sutherland HG, Martin DI, et al. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet. 1999;23:314-318.
33. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol. 2003;23:5293-5300.
34. Chamorro-Garcia R, Sahu M, Abbey RJ, et al. Transgenerational inheritance of increased fat depot size, stem cell reprogramming, and hepatic steatosis elicited by prenatal exposure to the obesogen tributyltin in mice. Environ Health Perspect. 2013;121:359-366.
35. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.
36. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7-G17.
37. Cattanach BM, Kirk M. Differential activity of maternally and paternally derived chromosome regions in mice. Nature. 1985;315:496-498.
38. Ferguson-Smith AC. Genomic imprinting: the emergence of an epigenetic paradigm. Nat Rev Genet. 2011;12:565-575.
39. McGrath J, Solter D. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell. 1984;37:179-183.
40. Surani MA, Barton SC, Norris ML. Nuclear transplantation in the mouse: heritable differences between parental genomes after activation of the embryonic genome. Cell. 1986;45:127-136.
41. Wood AJ, Oakey RJ. Genomic imprinting in mammals: emerging themes and established theories. PLoS Genet. 2006;2:e147.
42. Plagge A, Gordon E, Dean W, et al. The imprinted signaling protein XL alpha s is required for postnatal adaptation to feeding. Nat Genet. 2004;36: 818-826.
43. Smith ER, Lee MG, Winter B, et al. Drosophila UTX is a histone H3 Lys27 demethylase that colocalizes with the elongating form of RNA polymerase II. Mol Cell Biol. 2008;28:1041-1046.
44. Ferguson-Smith MA, Yang F, Rens W, et al. The impact of chromosome sorting and painting on the comparative analysis of primate genomes. Cytogenet Genome Res. 2005;108:112-121.
45. Garfield AS, Cowley M, Smith FM, et al. Distinct physiological and behavioural functions for parental alleles of imprinted Grb10. Nature. 2011;469:534-538.
46. Ferron SR, Charalambous M, Radford E, et al. Postnatal loss of Dlk1 imprinting in stem cells and niche astrocytes regulates neurogenesis. Nature. 2011;475:381-385.
47. Cowley M, Garfield AS, Madon-Simon M, et al. Developmental programming mediated by complementary roles of imprinted grb10 in mother and pup. PLoS Biol. 2014;12:e1001799.
48. Yamazawa K, Kagami M, Nagai T, et al. Molecular and clinical findings and their correlations in Silver-Russell syndrome: implications for a positive role of IGF2 in growth determination and differential imprinting regulation of the IGF2-H19 domain in bodies and placentas. J Mol Med (Berl). 2008;86:1171-1181.
49. Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2010;18:8-14.
50. Cassidy SB, Dykens E, Williams CA. Prader-Willi and Angelman syndromes: sister imprinted disorders. Am J Med Genet. 2000;97: 136-146.
51. Soejima H, Nakagawachi T, Zhao W, et al. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer. Oncogene. 2004;23:4380-4388.
52. Lim DH, Maher ER. Genomic imprinting syndromes and cancer. Adv Genet. 2010;70:145-175.
53. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753-1755.
54. Akolkar PN, Gulwani-Akolkar B, Heresbach D, et al. Differences in risk of Crohn's disease in offspring of mothers and fathers with inflammatory bowel disease. Am J Gastroenterol. 1997;92:2241-2244.
55. Zelinkova Z, Stokkers PC, van der Linde K, et al. Maternal imprinting and female predominance in familial Crohn's disease. J Crohns Colitis. 2012;6:771-776.
56. Fransen K, Mitrovic M, van Diemen CC, et al. Limited evidence for parent-of-origin effects in inflammatory bowel disease associated loci. PLoS One. 2012;7:e45287.
57. Chen T, Li E. Establishment and maintenance of DNA methylation patterns in mammals. Curr Top Microbiol Immunol. 2006;301:179-201.
58. Hermann A, Goyal R, Jeltsch A. The Dnmt1 DNA-(cytosine-C5)- methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem. 2004;279:48350-48359.
59. Cooper DN, Gerber-Huber S. DNA methylation and CpG suppression. Cell Differ. 1985;17:199-205.
60. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene. 2002;21:5380-5387.
61. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484-492.
62. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007;39:457-466.
63. Han H, Cortez CC, Yang X, et al. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet. 2011;20:4299-4310.
64. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41:178-186.
65. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009; 41:1350-1353.
66. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell. 1999;99:451-454.
67. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006;38: 149-153.
68. Sproul D, Nestor C, Culley J, et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A. 2011;108:4364-4369.
69. Sproul D, Kitchen RR, Nestor CE, et al. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol. 2012;13:R84.
70. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9:2395-2402.
71. Goll MG, Kirpekar F, Maggert KA, et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science. 2006;311:395-398.
72. Bourc'his D, Xu GL, Lin CS, et al. Dnmt3L and the establishment of maternal genomic imprints. Science. 2001;294:2536-2539.
73. Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc Natl Acad Sci U S A. 2002;99:16916-16921.
74. Van Emburgh BO, Robertson KD. Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants. Nucleic Acids Res. 2011;39:4984-5002.
75. Gowher H, Jeltsch A. Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from mouse: the enzyme modifies DNA in a non-processive manner and also methylates non-CpG [correction of non-CpA] sites. J Mol Biol. 2001;309:1201-1208.
76. Suetake I, Miyazaki J, Murakami C, et al. Distinct enzymatic properties of recombinant mouse DNA methyltransferases Dnmt3a and Dnmt3b. J Biochem. 2003;133:737-744.
77. Yokochi T, Robertson KD. Preferential methylation of unmethylated DNA by mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem. 2002;277:11735-11745.
78. Fatemi M, Hermann A, Gowher H, et al. Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem. 2002;269:4981-4984.
79. Lorincz MC, Schubeler D, Hutchinson SR, et al. DNA methylation density influences the stability of an epigenetic imprint and Dnmt3a/bindependent de novo methylation. Mol Cell Biol. 2002;22:7572-7580.
80. Chen T, Ueda Y, Dodge JE, et al. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol. 2003;23:5594-5605.
81. Liang G, Chan MF, Tomigahara Y, et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002;22:480-491.
82. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992;69:915-926.
83. Biniszkiewicz D, Gribnau J, Ramsahoye B, et al. Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality. Mol Cell Biol. 2002;22:2124-2135.
84. Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247-257.
85. Harris RA, Nagy-Szakal D, Pedersen N, et al. Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:2334-2341.
86. Lin Z, Hegarty JP, Cappel JA, et al. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet. 2011;80:59-67.
87. Lin Z, Hegarty JP, Yu W, et al. Identification of disease-associated DNA methylation in B cells from Crohn's disease and ulcerative colitis patients. Dig Dis Sci. 2012;57:3145-3153.
88. Nimmo ER, Prendergast JG, Aldhous MC, et al. Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inflamm Bowel Dis. 2012;18:889-899.
89. Cooke J, Zhang H, Greger L, et al. Mucosal genome-wide methylation changes in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18: 2128-2137.
90. Hasler R, Feng Z, Backdahl L, et al. A functional methylome map of ulcerative colitis. Genome Res. 2012;22:2130-2137.
91. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573-3577.
92. Saito S, Kato J, Hiraoka S, et al. DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis. 2011;17:1955-1965.
93. Wheeler JM, Kim HC, Efstathiou JA, et al. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut. 2001;48:367-371.
94. Kouzarides T. Chromatin modifications and their function. Cell. 2007; 128:693-705.
95. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet. 2007;8:286-298.
96. Zentner GE, Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol. 2013;20:259-266.
97. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-45.
98. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293: 1074-1080.
99. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol. 2010;28: 817-825.
100. Henikoff S, Shilatifard A. Histone modification: cause or cog? Trends Genet. 2011;27:389-396.
101. Selvi BR, Mohankrishna DV, Ostwal YB, et al. Small molecule modulators of histone acetylation and methylation: a disease perspective. Biochim Biophys Acta. 2010;1799:810-828.
102. Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene. 2012;31:4257-4265.
103. Szerlong HJ, Hansen JC. Nucleosome distribution and linker DNA: connecting nuclear function to dynamic chromatin structure. Biochem Cell Biol. 2011;89:24-34.
104. Parmar JJ, Marko JF, Padinhateeri R. Nucleosome positioning and kinetics near transcription-start-site barriers are controlled by interplay between active remodeling and DNA sequence. Nucleic Acids Res. 2014;42:128-136.
105. Chodavarapu RK, Feng S, Bernatavichute YV, et al. Relationship between nucleosome positioning and DNA methylation. Nature. 2010; 466:388-392.
106. Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 2010;463:474-484.
107. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009;28:1653-1668.
108. Erdel F, Rippe K. Chromatin remodelling in mammalian cells by ISWItype complexes-where, when and why? FEBS J. 2011;278:3608-3618.
109. Bowen NJ, Fujita N, Kajita M, et al. Mi-2/NuRD: multiple complexes for many purposes. Biochim Biophys Acta. 2004;1677:52-57.
110. Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007;26:5433-5438.
111. Vincent JA, Kwong TJ, Tsukiyama T. ATP-dependent chromatin remodeling shapes the DNA replication landscape. Nat Struct Mol Biol. 2008; 15:477-484.
112. Shimada K, Oma Y, Schleker T, et al. Ino80 chromatin remodeling complex promotes recovery of stalled replication forks. Curr Biol. 2008;18:566-575.
113. Conaway RC, Conaway JW. The INO80 chromatin remodeling complex in transcription, replication and repair. Trends Biochem Sci. 2009;34:71-77.
114. Lu LF, Liston A. MicroRNA in the immune system, microRNA as an immune system. Immunology. 2009;127:291-298.
115. Bronevetsky Y, Ansel KM. Regulation of miRNA biogenesis and turnover in the immune system. Immunol Rev. 2013;253:304-316.
116. Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell. 2010;140:859-870.
117. Kelsall BL. Innate and adaptive mechanisms to control [corrected] pathological intestinal inflammation. J Pathol. 2008;214:242-259.
118. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun. 2011;3:550-564.
119. Zhou L, Braat H, Faber KN, et al. Monocytes and their pathophysiological role in Crohn's disease. Cell Mol Life Sci. 2009;66:192-202.
120. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62:1653-1664.
121. Tezuka H, Ohteki T. Regulation of intestinal homeostasis by dendritic cells. Immunol Rev. 2010;234:247-258.
122. Kayama H, Takeda K. Regulation of intestinal homeostasis by innate and adaptive immunity. Int Immunol. 2012;24:673-680.
123. Ivashkiv LB. Epigenetic regulation of macrophage polarization and function. Trends Immunol. 2013;34:216-223.
124. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787-795.
125. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011;9:355-361.
126. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109:17537-17542.
127. Zhang Z, Maurer K, Perin JC, et al. Cytokine-induced monocyte characteristics in SLE. J Biomed Biotechnol. 2010;2010:507475.
128. Campesi I, Sanna M, Zinellu A, et al. Oral contraceptives modify DNA methylation and monocyte-derived macrophage function. Biol Sex Differ. 2012;3:4.
129. Huang Y, Min S, Lui Y, et al. Global mapping of H3K4me3 and H3K27me3 reveals chromatin state-based regulation of human monocytederived dendritic cells in different environments. Genes Immun. 2012;13: 311-320.
130. Zanette DL, van Eggermond MC, Haasnoot G, et al. Simvastatin reduces CCL2 expression in monocyte-derived cells by induction of a repressive CCL2 chromatin state. Hum Immunol. 2014;75:10-14.
131. Wen H, Schaller MA, Dou Y, et al. Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. J Leukoc Biol. 2008;83:439-446.
132. Wen H, Dou Y, Hogaboam CM, et al. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood. 2008;111:1797-1804.
133. Kim HP, Lee YS, Park JH, et al. Transcriptional and epigenetic networks in the development and maturation of dendritic cells. Epigenomics. 2013;5:195-204.
134. Fournier BM, Parkos CA. The role of neutrophils during intestinal inflammation. Mucosal Immunol. 2012;5:354-366.
135. Ishii M, Asano K, Namkoong H, et al. CRTH2 is a critical regulator of neutrophil migration and resistance to polymicrobial sepsis. J Immunol. 2012;188:5655-5664.
136. Maruyama K, Fukasaka M, Vandenbon A, et al. The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation. Immunity. 2012;37:1024-1036.
137. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (∗). Annu Rev Immunol. 2010;28:445-489.
138. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol. 2009;9:91-105.
139. Allan RS, Zueva E, Cammas F, et al. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature. 2012;487:249-253.
140. Zhu J. Transcriptional regulation of Th2 cell differentiation. Immunol Cell Biol. 2010;88:244-249.
141. Janson PC, Winerdal ME, Winqvist O. At the crossroads of T helper lineage commitment-epigenetics points the way. Biochim Biophys Acta. 2009;1790:906-919.
142. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 2013;121:2402-2414.
143. Kanno Y, Vahedi G, Hirahara K, et al. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu Rev Immunol. 2012;30:707-731.
144. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-564.
145. Katoh H, Zheng P, Liu Y. FOXP3: genetic and epigenetic implications for autoimmunity. J Autoimmun. 2013;41:72-78.
146. Katoh H, Qin ZS, Liu R, et al. FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. Mol Cell. 2011;44:770-784.
147. Zheng Y, Josefowicz SZ, Kas A, et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007; 445:936-940.
148. Schmidl C, Klug M, Boeld TJ, et al. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res. 2009;19:1165-1174.
149. Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599-608.
150. Leung CH, Lam W, Ma DL, et al. Butyrate mediates nucleotide-binding and oligomerisation domain (NOD) 2-dependent mucosal immune responses against peptidoglycan. Eur J Immunol. 2009;39:3529-3537.
151. Malo MS, Biswas S, Abedrapo MA, et al. The pro-inflammatory cytokines, IL-1beta and TNF-alpha, inhibit intestinal alkaline phosphatase gene expression. DNA Cell Biol. 2006;25:684-695.
152. Angrisano T, Pero R, Peluso S, et al. LPS-induced IL-8 activation in human intestinal epithelial cells is accompanied by specific histone H3 acetylation and methylation changes. BMC Microbiol. 2010;10:172.
153. Schmeck B, Beermann W, van Laak V, et al. Intracellular bacteria differentially regulated endothelial cytokine release by MAPK-dependent histone modification. J Immunol. 2005;175:2843-2850.
154. Schmeck B, Lorenz J, N'Guessan PD, et al. Histone acetylation and flagellin are essential for Legionella pneumophila-induced cytokine expression. J Immunol. 2008;181:940-947.
155. Slevogt H, Schmeck B, Jonatat C, et al. Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. Am J Physiol Lung Cell Mol Physiol. 2006;290:L818-L826.
156. Haller D, Holt L, Kim SC, et al. Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J Biol Chem. 2003; 278:23851-23860.
157. Hamon MA, Cossart P. Histone modifications and chromatin remodeling during bacterial infections. Cell Host Microbe. 2008;4:100-109.
158. Fehri LF, Rechner C, Janssen S, et al. Helicobacter pylori-induced modification of the histone H3 phosphorylation status in gastric epithelial cells reflects its impact on cell cycle regulation. Epigenetics. 2009;4:577-586.
159. Ding SZ, Fischer W, Kaparakis-Liaskos M, et al. Helicobacter pyloriinduced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS One. 2010;5:e9875.
160. Angrisano T, Lembo F, Peluso S, et al. Helicobacter pylori regulates iNOS promoter by histone modifications in human gastric epithelial cells. Med Microbiol Immunol. 2012;201:249-257.
161. Ghadimi D, Helwig U, Schrezenmeir J, et al. Epigenetic imprinting by commensal probiotics inhibits the IL-23/IL-17 axis in an in vitro model of the intestinal mucosal immune system. J Leukoc Biol. 2012;92:895-911.
162. Gonsky R, Deem RL, Landers CJ, et al. Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens. Inflamm Bowel Dis. 2011;17:171-178.
163. Mohamadzadeh M, Pfeiler EA, Brown JB, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4623-4630.
164. Lightfoot YL, Yang T, Sahay B, et al. Targeting aberrant colon cancerspecific DNA methylation with lipoteichoic acid-deficient Lactobacillus acidophilus. Gut Microbes. 2013;4:84-88.
165. Lightfoot YL, Mohamadzadeh M. Tailoring gut immune responses with lipoteichoic acid-deficient Lactobacillus acidophilus. Front Immunol. 2013;4:25.
166. Takahashi K, Sugi Y, Hosono A, et al. Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis. J Immunol. 2009;183:6522-6529.
167. Takahashi K, Sugi Y, Nakano K, et al. Epigenetic control of the host gene by commensal bacteria in large intestinal epithelial cells. J Biol Chem. 2011;286:35755-35762.
168. Kellermayer R, Dowd SE, Harris RA, et al. Colonic mucosal DNA methylation, immune response, and microbiome patterns in Toll-like receptor 2-knockout mice. FASEB J. 2011;25:1449-1460.
169. Yin L, Chung WO. Epigenetic regulation of human beta-defensin 2 and CC chemokine ligand 20 expression in gingival epithelial cells in response to oral bacteria. Mucosal Immunol. 2011;4:409-419.
170. Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science. 2012;336:489-493.
171. Kellermayer R, Balasa A, Zhang W, et al. Epigenetic maturation in colonic mucosa continues beyond infancy in mice. Hum Mol Genet. 2010;19:2168-2176.
172. Schaible TD, Harris RA, Dowd SE, et al. Maternal methyl-donor supplementation induces prolonged murine offspring colitis susceptibility in association with mucosal epigenetic and microbiomic changes. Hum Mol Genet. 2011;20:1687-1696.
173. Nagy-Szakal D, Ross MC, Dowd SE, et al. Maternal micronutrients can modify colonic mucosal microbiota maturation in murine offspring. Gut Microbes. 2012;3:426-433.
174. Mir SA, Nagy-Szakal D, Dowd SE, et al. Prenatal methyl-donor supplementation augments colitis in young adult mice. PLoS One. 2013;8:e73162.
175. Rakyan VK, Down TA, Balding DJ, et al. Epigenome-wide association studies for common human diseases. Nat Rev Genet. 2011;12:529-541.
176. Tsaprouni LG, Ito K, Powell JJ, et al. Differential patterns of histone acetylation in inflammatory bowel diseases. J Inflamm (Lond). 2011;8:1.
177. Sadler T, Scarpa M, Rieder F, et al. Cytokine-induced chromatin modifications of the type I collagen alpha 2 gene during intestinal endothelial-tomesenchymal transition. Inflamm Bowel Dis. 2013;19:1354-1364.
178. McKenna LB, Schug J, Vourekas A, et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology. 2010;139:1654-1664, 1664 e1651.
179. De Iudicibus S, Lucafo M, Martelossi S, et al. MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. World J Gastroenterol. 2013;19:7947-7954.
180. Coskun M, Bjerrum JT, Seidelin JB, et al. MicroRNAs in inflammatory bowel disease-pathogenesis, diagnostics and therapeutics. World J Gastroenterol. 2012;18:4629-4634.
181. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet. 1975;2:58-60.
182. Peterson AJ, Menheniott TR, O'Connor L, et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology. 2010;139:2005-2017.
183. Tomita H, Takaishi S, Menheniott TR, et al. Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology. 2011;140:879-891.
184. Cheng AS, Li MS, Kang W, et al. Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology. 2013;144:122-133.e129.
185. Schmid CA, Muller A. FoxD3 is a novel, epigenetically regulated tumor suppressor in gastric carcinogenesis. Gastroenterology. 2013;144:22-25.
186. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458-466.
187. Hartnett L, Egan LJ. Inflammation, DNA methylation and colitisassociated cancer. Carcinogenesis. 2012;33:723-731.
188. Hahn MA, Hahn T, Lee DH, et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 2008;68: 10280-10289.
189. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1: 239-259.
190. Duffy MJ, Napieralski R, Martens JW, et al. Methylated genes as new cancer biomarkers. Eur J Cancer. 2009;45:335-346.
191. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-96.
192. Konishi K, Shen L, Wang S, et al. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 2007; 132:1254-1260.
193. Azarschab P, Porschen R, Gregor M, et al. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer. 2002;35: 121-126.
194. Moriyama T, Matsumoto T, Nakamura S, et al. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis Colon Rectum. 2007;50:1384-1392.
195. Wang FY, Arisawa T, Tahara T, et al. Aberrant DNA methylation in ulcerative colitis without neoplasia. Hepatogastroenterology. 2008;55:62-65.
196. Dhir M, Montgomery EA, Glockner SC, et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg. 2008;12:1745-1753.
197. Li Y, de Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010;59:227-235.
198. Olaru AV, Cheng Y, Agarwal R, et al. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. Inflamm Bowel Dis. 2012;18:641-648.
199. Hmadcha A, Bedoya FJ, Sobrino F, et al. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med. 1999;190:1595-1604.
200. Foran E, Garrity-Park MM, Mureau C, et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res. 2010;8:471-481.
201. Kominsky DJ, Keely S, MacManus CF, et al. An endogenously antiinflammatory role for methylation in mucosal inflammation identified through metabolite profiling. J Immunol. 2011;186:6505-6514.
202. O'Hagan HM, Wang W, Sen S, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell. 2011;20:606-619.
203. Li Y, Deuring J, Peppelenbosch MP, et al. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis. 2012;33:1889-1896.
204. Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients. Inflamm Bowel Dis. 2013;19:165-173.
205. Papadia C, Louwagie J, Del Rio P, et al. FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis-associated colorectal neoplasia. Inflamm Bowel Dis. 2014;20:271-277.
206. Tahara T, Shibata T, Nakamura M, et al. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med. 2009;9:125-130.
207. Tahara T, Shibata T, Nakamura M, et al. Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int J Mol Med. 2009;23: 521-527.
208. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, et al. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitisassociated colorectal cancer. Am J Gastroenterol. 2010;105:1610-1619.
209. Kim SW, Kim ES, Moon CM, et al. Abnormal genetic and epigenetic changes in signal transducer and activator of transcription 4 in the pathogenesis of inflammatory bowel diseases. Dig Dis Sci. 2012;57:2600-2607.
210. Zahm AM, Thayu M, Hand NJ, et al. Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2011; 53:26-33.
211. Fasseu M, Treton X, Guichard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One. 2010;5.
212. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008;135:1624-1635.e1624.
213. Duttagupta R, DiRienzo S, Jiang R, et al. Genome-wide maps of circulating miRNA biomarkers for ulcerative colitis. PLoS One. 2012;7:e31241.
214. Wu F, Guo NJ, Tian H, et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2011; 17:241-250.
215. Coskun M, Bjerrum JT, Seidelin JB, et al. miR-20b, miR-98, miR-125b-1∗, and let-7e∗as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol. 2013;19:4289-4299.
216. Iborra M, Bernuzzi F, Correale C, et al. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clin Exp Immunol. 2013;173:250-258.
217. Glauben R, Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med. 2011;17:426-433.
218. Edwards AJ, Pender SL. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases. Biochem Soc Trans. 2011;39: 1092-1095.
219. Rosen MJ, Frey MR, Washington MK, et al. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm Bowel Dis. 2011;17:2224-2234.
220. Wang LS, Kuo CT, Stoner K, et al. Dietary black raspberries modulate DNA methylation in dextran sodium sulfate (DSS)-induced ulcerative colitis. Carcinogenesis. 2013;34:2842-2850.
221. Macfarlane AJ, Behan NA, Matias FM, et al. Dietary folate does not significantly affect the intestinal microbiome, inflammation or tumorigenesis in azoxymethane-dextran sodium sulphate-treated mice. Br J Nutr. 2013;109:630-638.
222. Chen M, Peyrin-Biroulet L, George A, et al. Methyl deficient diet aggravates experimental colitis in rats. J Cell Mol Med. 2011;15: 2486-2497.
223. Yara S, Lavoie JC, Beaulieu JF, et al. Iron-ascorbate-mediated lipid peroxidation causes epigenetic changes in the antioxidant defense in intestinal epithelial cells: impact on inflammation. PLoS One. 2013; 8:e63456.
224. O'Gorman A, Colleran A, Ryan A, et al. Regulation of NF-kappaB responses by epigenetic suppression of IkappaBalpha expression in HCT116 intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2010;299:G96-G105.
225. Turgeon N, Moore Gagne J, Blais M, et al. The acetylome regulators Hdac1 and Hdac2 differently modulate intestinal epithelial cell dependent homeostatic responses in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2014;306:G594-G605.
226. Meng X, Zhang Y, Jia Z, et al. A novel tylophorine analog W-8 upregulates forkhead boxP3 expression and ameliorates murine colitis. J Leukoc Biol. 2013;93:83-93.
227. Singh NP, Singh UP, Singh B, et al. Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS One. 2011;6:e23522.